Alexandra Monceau,Rasya Gokul Nath,Xavier Suárez-Calvet,Olimpia Musumeci,Antonio Toscano,Biruta Kierdaszuk,Anna Kostera-Pruszczyk,Cristina Domínguez- González,Aurelio Hernández-Lain,Carmen Paradas,Eloy Rivas,George Papadimas,Constantinos Papadopoulos,Margarita Chrysanthou-Piterou,Eduard Gallardo,Montse Olivé,James Lilleker,Mark E Roberts,Domenica Marchese,Giulia Lunazzi,Holger Heyn,Esther Fernández-Simón,Elisa Villalobos,James Clark,Panos Katsikis,Catherine Collins,Priyanka Mehra,Zoe Laidler,Amy Vincent,Giorgio Tasca,Chiara Marini-Bettolo,Michela Guglieri,Volker Straub,Nina Raben,Jordi Díaz-Manera

Abstract:Late-onset Pompe Disease (LOPD) is a rare genetic disorder caused by the deficiency of acid alpha-glucosidase leading to progressive cellular dysfunction due to the accumulation of glycogen in the lysosome. The mechanism of relentless muscle damage – a classic manifestation of the disease – has been extensively studied by analysing the whole muscle tissue; however, little, if any, is known about transcriptional heterogeneity among nuclei within the multinucleated skeletal muscle cells. This is the first report of application of single nuclei RNA sequencing to uncover changes in the gene expression profile in muscle biopsies from eight patients with LOPD and four muscle samples from age and gender matched healthy controls. We matched these changes with histology findings using GeoMx Spatial Transcriptomics to compare the transcriptome of control myofibers from healthy individuals with non-vacuolated (histologically unaffected) and vacuolated (histologically affected) myofibers of LODP patients. We observed an increase in the proportion of slow and regenerative muscle fibers and macrophages in LOPD muscles. The expression of the genes involved in glycolysis was reduced, whereas the expression of the genes involved in the metabolism of lipids and amino acids was increased in non-vacuolated fibers, indicating early metabolic abnormalities. Additionally, we detected upregulation of autophagy genes, and downregulation of the genes involved in ribosomal and mitochondrial function leading to defective oxidative phosphorylation. The upregulation of the genes associated with inflammation, apoptosis and muscle regeneration was observed only in vacuolated fibers. Notably, enzyme replacement therapy – the only available therapy for the disease – showed a tendency to restore metabolism dysregulation, particularly within slow fibers. A combination of single nuclei RNA sequencing and spatial transcriptomics revealed the landscape of normal and the diseased muscle, and highlighted the early abnormalities associated with the disease progression. Thus, the application of these two new cutting-edge technologies provided insight into the molecular pathophysiology of muscle damage in LOPD and identified potential avenues for therapeutic intervention.

Combined miRNA transcriptome and proteome analysis of extracellular vesicles in urine and blood from the Pompe mouse model

Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease

Ultrastructural and diffusion tensor imaging studies reveal axon abnormalities in Pompe disease mice

Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

Immortalization of murine muscle cells from lysosomal alpha-glucosidase deficient mice: a new tool to study pathophysiology and assess therapeutic strategies for Pompe disease

GAA Compound Heterozygous Mutations Associated with Autophagic Impairment Cause Cerebral Infarction in Pompe Disease

Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease

Non-invasive optoacoustic imaging of glycogen-storage and muscle degeneration in late-onset Pompe disease

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease

Decoding the muscle transcriptome of patients with late onset Pompe disease reveals markers of disease progression

Analyzing immune cell infiltrates in skeletal muscle of infantile-onset Pompe disease using bioinformatics and machine learning

Interplay between mitochondrial dysfunction and lysosomal storage: challenges in genetic metabolic muscle diseases with a focus on infantile onset Pompe disease

Pompe Disease in China: Clinical and Molecular Characteristics

Defect in degradation of glycogenin‐exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Degeneration of muscle spindles in a murine model of Pompe disease

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

Molecular Approaches for the Treatment of Pompe Disease

Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease

Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China